Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04940624 · ClinicalTrials.gov registry record · Phase 3
A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome
A Phase 3 study of Dravet Syndrome (DS), sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 144
- Enrollment target
- 20
- Study locations
NCT04940624 is a Phase 3 study of Dravet Syndrome (DS) that has completed, run by Takeda. The registered enrollment target is 144 participants. The trial reports 20 study locations across 17 states.
The verdict
NCT04940624, a Phase 3 study of Dravet Syndrome (DS), has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 144 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main aim of the study is to learn if soticlestat, when given as an add-on therapy, reduces the number of convulsive seizures in children and young adults with DS. Participants will receive their standard antiseizure therapy, plus either a tablet of soticlestat or placebo for 16 weeks. A placebo looks just like soticlestat but will not have any medicine in it. Participants may continue treatment in an extension study, based on the extension study's entry criteria. Those that want to stop treatment will have a gradual dose reduction during 1 week and then be followed up for 2 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Soticlestat
Study Locations (20)
California
- David Geffen School of Medicine at UCLA - Los Angeles
- University of California Benioff Children's Hospital - San Francisco
Washington
- Seattle Children's Hospital - Seattle
- Multicare Health System - Mary Bridge Pediatrics - Tacoma
Beijing Municipality
- Peking University First Hospital - Beijing
- Beijing Children's Hospital,Capital Medical University - Beijing
Arizona
- Phoenix Childrens Hospital - Phoenix
Georgia
- Clinical Integrative Research Center of Atlanta - Atlanta
Iowa
- University of Iowa Hospitals & Clinics - (CRS) - Iowa City
New York
- NYU Comprehensive Epilepsy Center - New York
Ohio
- University of Toledo - Toledo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2021-10-28 |
| Est. Completion | 2024-04-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04940624
The ClinicalTrials.gov registry entry for NCT04940624 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dravet Syndrome (DS) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04940624 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Washington, Beijing Municipality.
Frequently Asked Questions
What is clinical trial NCT04940624 about?
NCT04940624 is a clinical study titled "A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome". The main aim of the study is to learn if soticlestat, when given as an add-on therapy, reduces the number of convulsive seizures in children and young adults with DS. Participants will receive their standard antiseizure therapy, plus either a tablet of soticlestat or placebo for 16 weeks. A placebo...
What is the current status of trial NCT04940624?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 144 participants. The study started on 2021-10-28. Estimated completion is 2024-04-11.
What conditions does trial NCT04940624 study?
This clinical trial studies the following conditions: Dravet Syndrome (DS).
What interventions are being tested in trial NCT04940624?
The interventions under investigation include: Placebo (DRUG), Soticlestat (DRUG).
Who is sponsoring clinical trial NCT04940624?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04940624 being conducted?
This trial has 20 study locations across Arizona, California, Georgia, Iowa, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dravet Syndrome (DS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.